Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants

Emerging SARS-CoV-2 variants have accrued mutations within the spike protein rendering most therapeutic monoclonal antibodies against COVID-19 ineffective. Hence there is an unmet need for broad-spectrum mAb treatments for COVID-19 that are more resistant to antigenically drifted SARS-CoV-2 variants...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Wenjuan, Janssens, Rick, Mykytyn, Anna Z., Li, Wentao, Drabek, Dubravka, van Haperen, Rien, Chatziandreou, Marianthi, Rissmann, Melanie, van der Lee, Joline, van Dortmondt, Melissa, Martin, Itziar Serna, van Kuppeveld, Frank J. M., Hurdiss, Daniel L., Haagmans, Bart L., Grosveld, Frank, Bosch, Berend-Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990171/
https://www.ncbi.nlm.nih.gov/pubmed/36895554
http://dx.doi.org/10.3389/fimmu.2023.1111385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990171/
https://www.ncbi.nlm.nih.gov/pubmed/36895554
http://dx.doi.org/10.3389/fimmu.2023.1111385

Ejemplares similares